Print

HVTN 086, SAAVI 103

Phase I, placebo-controlled clinical trial to evaluate the safety and immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis subtype C gp140 with MF59 adjuvant in various vaccinia-na?ve adult participants in South Africa

Trial Details:

I Ongoing
South African AIDS Vaccine Initiative (SAAVI), HIV Vaccine Trials Network (HVTN) June 30, 2011
SAAVI DNA-C2,SAAVI MVA-C,Oligomeric gp140/MF59 DNA gag, rev, tat, nef, env C; MVA gag, rev, tat, nef env C
SAAVI MVA-C Viral Vector - Pox
SAAVI DNA-C2 DNA
Oligomeric gp140/MF59 Protein
MF59
South Africa 184
NCT01418235
http://clinicaltrials.gov/ct2/show/NCT01418235?term=hiv+vaccine&lup_s=07%2F18%2F2011&lup_d=30